BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND NF1, NFNS, 4763, ENSG00000196712, P21359
87 results:

  • 1. Somatic Genomic and Transcriptomic Characterization of Primary ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
    J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Survey of nf1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
    Köbel M; Yang RZ; Kang EY; Al-Shamma Z; Cook LS; Kinloch M; Carey MS; Hopkins L; Nelson GS; McManus KJ; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Fu Y; Reuss DE; Lee CH
    Gynecol Oncol; 2023 Nov; 178():80-88. PubMed ID: 37820398
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
    Nguyen NT; Raetz A; Montoya D; Schilling V; Tong C; Brooks RA; Leiserowitz G; Chien J
    Gynecol Oncol; 2023 Nov; 178():69-79. PubMed ID: 37806229
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
    McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ
    Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and ovarian cancer.
    Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
    JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.
    Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
    J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital.
    Oliveira MJ; Costa S; Magalhães A; Garrido L; Peleteiro B; Fougo JL; Castedo S
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11145-11156. PubMed ID: 37347260
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations.
    Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Dvořák J; Němejcová K; Matěj R; Laco J; Drozenová J; Fabian P; Hausnerová J; Méhes G; Škapa P; Švajdler M; Cibula D; Frühauf F; Bártů MK; Dundr P
    Diagn Pathol; 2023 Jun; 18(1):72. PubMed ID: 37303048
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
    Foster KI; Shaw KRM; Jin J; Westin SN; Yap TA; Glassman DM; Jazaeri AA; Rauh-Hain JA; Lee S; Fellman BM; Ju Z; Liu Y; Fleming ND; Sood AK
    Cancer; 2023 Jun; 129(11):1672-1680. PubMed ID: 36930815
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
    Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
    Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Prevalence of Pathogenic Germline Mutations in 13 Hereditary cancer-Related Genes in Breast cancer Patients in Narathiwat Province, Thailand.
    Sukpan P; Kanokwiroon K; Sriplung H; Laochareonsuk W; Choochuen P; Auseng N; Wanawanakorn K; Sangkhathat S
    Asian Pac J Cancer Prev; 2023 Feb; 24(2):525-530. PubMed ID: 36853301
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
    Gan M; Tai Z; Yu Y; Zhang C; Xu J
    PeerJ; 2023; 11():e14653. PubMed ID: 36721777
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.
    Macklin-Mantia SK; Clift KE; Maimone S; Hodge DO; Riegert-Johnson D; Hines SL
    J Genet Couns; 2023 Jun; 32(3):598-606. PubMed ID: 36478495
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
    ElNaggar A; Robins D; Baca Y; Arguello D; Ulm M; Arend R; Mantia-Smaldone G; Chu C; Winer I; Holloway R; Krivak T; Jones N; Galvan-Turner V; Herzog TJ; Brown J
    Gynecol Oncol; 2022 Nov; 167(2):306-313. PubMed ID: 36229265
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Reminder for the clinician: abdominal manifestations of type 1 neurofibromatosis are not so uncommon.
    Portale G; Rulli R; Spolverato YC; Mascellino P
    BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 35918081
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
    Musacchio L; Califano D; Bartoletti M; Arenare L; Lorusso D; Losito NS; Cormio G; Greggi S; Raspagliesi F; Valabrega G; Salutari V; Pisano C; Spina A; Russo D; Del Sesto M; Canzonieri V; Ferraù F; Zannoni GF; Loizzi V; Ghizzoni V; Casanova C; Tuninetti V; Ducceschi M; Del Vecchio V; Scalone S; Priolo D; Perrone F; Scambia G; Pignata S
    Br J Cancer; 2022 Nov; 127(8):1479-1486. PubMed ID: 35869143
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. ovarian cell tumor in a child with neurofibromatosis type 1.
    Qutub LM; Al-Agha AE
    Ann Afr Med; 2022; 21(2):165-167. PubMed ID: 35848651
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
    Gerratana L; Movarek M; Wehbe F; Katam N; Mahalingam D; Donahue J; Shah A; Chae YK; Mulcahy M; Tsarwhas D; Villaflor V; Kalyan A; Hussein M; Patel J; Chandra S; Platanias LC; Gradishar W; Cristofanilli M; Behdad A
    JCO Precis Oncol; 2022 Jun; 6():e2100289. PubMed ID: 35772051
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
    Hou X; Zhai Y; Hu K; Liu CJ; Udager A; Pearce CL; Fearon ER; Cho KR
    Gynecol Oncol; 2022 Jun; 165(3):552-559. PubMed ID: 35414426
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. cancer genetics and breast cancer.
    Huber-Keener KJ
    Best Pract Res Clin Obstet Gynaecol; 2022 Jun; 82():3-11. PubMed ID: 35272929
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.